Abstract
Background/Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) affects up to 85% of patients receiving neurotoxic regimens, often leading to dose reduction and impaired quality of life, yet effective preventive or therapeutic options remain scarce. Emerging evidence implicates chemotherapy-induced gut microbiota dysbiosis in CIPN pathogenesis via a gut–nerve axis. Concurrently, rectal ozone insufflation (ROI) can modulate the gut microbiota and reduce inflammation. This narrative re-view aims to synthesise evidence on the role of gut dysbiosis in CIPN, evaluate the microbiota-modulating capacity of rectal ozone therapy (OT), and examine the biological plausibility of ozone as a microbiota-targeting intervention for CIPN. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and grey literature for studies published through March 2026 using terms related to CIPN, gut microbiota, dysbiosis, the gut–nerve axis, and OT. Preclinical studies, clinical reports, and systematic reviews were included and narratively synthesised according to the three objectives. Results: Neurotoxic agents induce dysbiosis marked by reduced microbial diversity, loss of short-chain fatty acid-producing bacteria, and expansion of pro-inflammatory taxa. Preclinical models demonstrate a causal role for specific microbial communities in CIPN, with microbiota depletion or faecal transplantation modulating neuropathic phenotypes. In human cohorts, dysbiosis severity correlates with CIPN symptoms. Preclinical studies show that ROI restores microbial balance, enhances short-chain fatty acid levels, and strengthens intestinal barrier function via Nrf2/HO-1 and sirtuin 1 (SIRT1) pathways. Preliminary retrospective data report sustained symptom improvement in CIPN patients receiving OT, though no study has directly linked ozone-induced microbiota changes to clinical outcomes. Conclusions: Convergent evidence supports a strong biological rationale for investi-gating ROI as a microbiota-targeting intervention in CIPN. However, high-quality randomised controlled trials with longitudinal microbiome profiling are needed to establish mechanistic causality and guide future supportive care strategies in oncology.
All Related Versions

This publication has 85 references indexed in Scilit: